Although the targets of biomanufacturing have evolved from therapeutic proteins to “advanced therapies” and now to gene therapies, the issues and solutions remain the same. The production of safe, ...
Regulatory approval is only one marker of success for biotherapeutics. Biotherapeutics must also be commercially feasible. Too high a price tag can lead to limited availability to the targeted patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results